Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Sponsor: Bristol-Myers Squibb
ClinicalTrials ID:NCT02719613
This study provides continued access to elotuzumab and/or other study drugs for participants from previous elotuzumab protocols who benefit from the treatment. Eligible participants must be 18 or older and currently receiving these drugs. Interventions include IV or oral administration of elotuzumab, dexamethasone, lenalidomide, bortezomib, pomalidomide, and nivolumab at prior study doses.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
Eligibility Criteria
Inclusion Criteria
- Participated in a previous elotuzumab protocol (including, but not limited to HuLuc63-1703, CA204007, CA204009, or CA204011) and is deemed by the investigator to be deriving benefit from elotuzumab and/or other study drugs as defined by the previous protocol
- Receiving elotuzumab and/or other study drugs at the time of signature of informed consent
- Males and Females, ages 18 and older
Exclusion Criteria
- All participants previously discontinued from an elotuzumab study for any reason
- Participants not receiving clinical benefit from previous study therapy
- Participants who are not medically well enough to receive study therapy as determined by the investigator
Other protocol defined inclusion/exclusion criteria could apply
Get This Program In Your Inbox
You can sign up and apply your patients for this program.